Kopran Limited (KOPRAN) AI Stock Analysis

Top Page

Kopran Limited

(NSE:KOPRAN)

Select Model

Rating:56Neutral

Price Target:INR 246.00▲(2.80% Upside)

Action:reiterated

Date:09/17/26

The score is held back primarily by weaker financial quality—especially persistently negative free cash flow and uneven profitability—despite healthy revenue growth and a manageable leverage profile. Technicals are strong with clear bullish trend signals, but momentum appears overbought, and the high P/E valuation limits upside confidence.

Positive Factors

Revenue GrowthRevenue growth accelerated materially in FY2026, indicating improving demand across the company’s pharmaceutical activities. Continued top-line expansion can support operating scale, broaden customer reach, and provide a stronger base for earnings recovery over the next several quarters.

Negative Factors

Persistently Negative Free Cash FlowPersistently negative free cash flow indicates that investment or working-capital requirements are absorbing more cash than the business generates after operations. If sustained, this reduces financial flexibility and may increase reliance on external funding to support growth.

Kopran Limited (KOPRAN) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 12.01B
Dividend Yield: 1.25%
Average Volume (3M): 64.60K
Price to Earnings (P/E): 46.2
Beta (1Y): 1.40
Revenue Growth: 11.96%
EPS Growth: -28.48%
Country: India
Employees: 1,156
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - General

Kopran Limited Business Overview & Revenue Model

Company Description

Kopran Limited is a fully integrated pharmaceutical entity that manufactures and distributes both active pharmaceutical ingredients (APIs) and finished drug products, serving markets in India and worldwide. Its extensive product portfolio includes a...

How the Company Makes Money

Kopran Limited primarily makes money by selling (1) finished pharmaceutical formulations (branded and/or generic medicines in dosage forms such as tablets, capsules, syrups, etc.) and (2) active pharmaceutical ingredients (APIs) supplied to other pha...

Kopran Limited Financial Statement Overview

Summary

Solid revenue growth (notably accelerating in FY2026), supported by a reasonably conservative balance sheet with moderate leverage. However, profitability has been volatile and free cash flow has been persistently negative in FY2022–FY2026, which materially weakens overall financial quality.

Income Statement

56Neutral

Balance Sheet

70Positive

Cash Flow

38Negative

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	7.00B	6.81B	6.30B	6.15B	5.48B	4.74B
Gross Profit	1.89B	1.60B	2.25B	2.09B	1.86B	1.90B
EBITDA	614.17M	623.00M	729.00M	868.18M	548.62M	980.11M
Net Income	249.83M	257.31M	385.52M	509.56M	272.33M	610.31M
Balance Sheet
Total Assets	0	9.08B	8.44B	7.43B	6.50B	6.11B
Cash, Cash Equivalents and Short-Term Investments	6.82M	72.22M	258.64M	80.91M	73.97M	58.68M
Total Debt	0	1.53B	1.48B	992.28M	752.38M	745.49M
Total Liabilities	-5.30B	3.78B	3.26B	2.52B	2.10B	1.85B
Stockholders Equity	5.30B	5.30B	5.18B	4.91B	4.39B	4.26B
Cash Flow
Free Cash Flow	234.30M	-105.46M	-134.46M	-133.56M	-270.22M	-757.47M
Operating Cash Flow	553.87M	565.79M	419.42M	432.58M	340.23M	-334.75M
Investing Cash Flow	-335.65M	-648.97M	-564.28M	-435.52M	-126.50M	-844.15M
Financing Cash Flow	-107.78M	-104.72M	258.68M	9.88M	-198.44M	1.23B

Kopran Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price239.30

Price Trends

50DMA248.71Negative

100DMA218.74Positive

200DMA180.84Positive

Market Momentum

MACD-1.94Positive

RSI40.55Neutral

STOCH21.09Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:KOPRAN, the sentiment is Negative. The current price of 239.30 is below the 20-day moving average (MA) of 262.53, below the 50-day MA of 248.71, and above the 200-day MA of 180.84, indicating a neutral trend. The MACD of -1.94 indicates Positive momentum. The RSI at 40.55 is Neutral, neither overbought nor oversold. The STOCH value of 21.09 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:KOPRAN.

Kopran Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:KOPRAN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:CIPLA	79Outperform	INR 1.11T	38.44	―	2.10%	-0.74%	-46.77%
IN:MARKSANS	78Outperform	INR 138.96B	26.84	―	0.29%	19.59%	47.58%
IN:SANOFI	70Outperform	INR 73.80B	20.24	―	3.84%	-5.74%	2.30%
IN:SMSPHARMA	62Neutral	INR 47.93B	45.49	―	0.08%	10.25%	33.78%
IN:KOPRAN	56Neutral	INR 11.56B	46.24	―	1.25%	11.96%	-28.48%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:NGLFINE	54Neutral	INR 15.76B	27.28	―	0.07%	40.45%	174.03%

* General Sector Average

Performance Comparison

IN:KOPRAN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:KOPRAN	Kopran Limited	239.30	76.27	46.78%
IN:CIPLA	Cipla Ltd	1380.00	-117.54	-7.85%
IN:MARKSANS	Marksans Pharma Limited	306.65	116.72	61.46%
IN:NGLFINE	NGL Fine-Chem Ltd.	2551.05	1006.52	65.17%
IN:SANOFI	Sanofi India Limited	3204.40	-1441.42	-31.03%
IN:SMSPHARMA	SMS Pharmaceuticals Limited	511.75	229.94	81.60%

Kopran Limited Corporate Events

Kopran Confirms SEBI Demat Compliance for September Quarter

Oct 12, 2026

Kopran Limited has confirmed compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The company stated that this certification is based on information provided by its r...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 17, 2026

Kopran Limited AI Stock Analysis